AFP mRNA level in enriched circulating tumor cells from hepatocellular carcinoma patient blood samples is a pivotal predictive marker for metastasis

Cancer Letters

Volumn 378, Issue 1, 2016, Pages 33-37

  Jin, Junhua ^a   Niu, Xiaojuan ^b   Zou, Lihui ^a   Li, Lin ^b   Li, Shugang ^c   Han, Jingli ^a   Zhang, Peiying ^c   Song, Jinghai ^b   Xiao, Fei ^a  

^a BEIJING HOSPITAL   (China)

^b BEIJING HOSPITAL   (China)

^c MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

Author keywords

Alpha fetoprotein; Circulating tumor cells; Hepatocellular carcinoma; Metastasis

Indexed keywords

ALPHA FETOPROTEIN; ANTIBODY EPITHELIAL CELL ADHESION MOLECULE NANOPARTICLE; MESSENGER RNA; NANOPARTICLE; TUMOR MARKER; UNCLASSIFIED DRUG; AFP PROTEIN, HUMAN; EPCAM PROTEIN, HUMAN; EPITHELIAL CELL ADHESION MOLECULE;

ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CELL LEVEL; CIRCULATING TUMOR CELL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; EARLY CANCER DIAGNOSIS; ENRICHMENT CULTURE; FEMALE; FOLLOW UP; HEPATOMA CELL; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; METASTASIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; BLOOD; CARCINOMA, HEPATOCELLULAR; DISEASE COURSE; GENETICS; HEP-G2 CELL LINE; IMMUNOLOGY; IMMUNOMAGNETIC SEPARATION; LIVER NEOPLASMS; METABOLISM; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SECONDARY; TIME FACTOR; TREATMENT OUTCOME; TUMOR EMBOLISM; UPREGULATION;

ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; EPITHELIAL CELL ADHESION MOLECULE; HEP G2 CELLS; HEPATECTOMY; HUMANS; IMMUNOMAGNETIC SEPARATION; LIVER NEOPLASMS; NEOPLASTIC CELLS, CIRCULATING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TIME FACTORS; TREATMENT OUTCOME; UP-REGULATION;

EID: 84979519908     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2016.04.033     Document Type: Article

References (27)

1. [1] Yu, M., Stott, S., Toner, M., Maheswaran, S., Haber, D.A., Circulating tumor cells: approaches to isolation and characterization. J. Cell Biol 192 (2011), 373–382.
2. [2] Pantel, K., Alix-Panabieres, C., Detection methods of circulating tumor cells. J. Thorac. Dis 4 (2012), 446–447.
3. [3] Pantel, K., Alix-Panabieres, C., The potential of circulating tumor cells as a liquid biopsy to guide therapy in prostate cancer. Cancer Discov 2 (2012), 974–975.
4. [4] Litvinov, S.V., Velders, M.P., Bakker, H.A., Fleuren, G.J., Warnaar, S.O., Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule. J. Cell Biol 125 (1994), 437–446.
5. [5] Allard, W.J., Matera, J., Miller, M.C., Repollet, M., Connelly, M.C., Rao, C., et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin. Cancer Res 10 (2004), 6897–6904.
6. [6] Riethdorf, S., Fritsche, H., Muller, V., Rau, T., Schindlbeck, C., Rack, B., et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin. Cancer Res 13 (2007), 920–928.
7. [7] Nagrath, S., Sequist, L.V., Maheswaran, S., Bell, D.W., Irimia, D., Ulkus, L., et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 450 (2007), 1235–1239.
8. [8] Hayes, D.F., Walker, T.M., Singh, B., Vitetta, E.S., Uhr, J.W., Gross, S., et al. Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer. Int. J. Oncol 21 (2002), 1111–1117.
9. [9] Attard, G., Swennenhuis, J.F., Olmos, D., Reid, A.H., Vickers, E., A'Hern, R., et al. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res 69 (2009), 2912–2918.
10. [10] Di Bisceglie, A.M., Hoofnagle, J.H., Elevations in serum alpha-fetoprotein levels in patients with chronic hepatitis B. Cancer 64 (1989), 2117–2120.
11. [11] Oka, H., Tamori, A., Kuroki, T., Kobayashi, K., Yamamoto, S., Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology 19 (1994), 61–66.
12. [12] Vora, S.R., Zheng, H., Stadler, Z.K., Fuchs, C.S., Zhu, A.X., Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma. Oncologist 14 (2009), 717–725.
13. [13] Yau, T., Yao, T.J., Chan, P., Wong, H., Pang, R., Fan, S.T., et al. The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib. Oncologist 16 (2011), 1270–1279.
14. [14] Bruix, J., Sherman, M., Llovet, J.M., Beaugrand, M., Lencioni, R., Burroughs, A.K., et al. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J. Hepatol 35 (2001), 421–430.
15. [15] Omata, M., Lesmana, L.A., Tateishi, R., Chen, P.J., Lin, S.M., Yoshida, H., et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol. Int 4 (2010), 439–474.
16. [16] Hu, K.Q., Kyulo, N.L., Lim, N., Elhazin, B., Hillebrand, D.J., Bock, T., Clinical significance of elevated alpha-fetoprotein (AFP) in patients with chronic hepatitis C, but not hepatocellular carcinoma. Am. J. Gastroenterol 99 (2004), 860–865.
17. [17] Wang, Y., Shen, Z., Zhu, Z., Han, R., Huai, M., Clinical values of AFP, GPC3 mRNA in peripheral blood for prediction of hepatocellular carcinoma recurrence following OLT: AFP, GPC3 mRNA for prediction of HCC. Hepat. Mon 11 (2011), 195–199.
18. [18] Marubashi, S., Dono, K., Nagano, H., Sugita, Y., Asaoka, T., Hama, N., et al. Detection of AFP mRNA-expressing cells in the peripheral blood for prediction of HCC recurrence after living donor liver transplantation. Transpl. Int 20 (2007), 576–582.
19. [19] Ijichi, M., Takayama, T., Matsumura, M., Shiratori, Y., Omata, M., Makuuchi, M., Alpha-fetoprotein mRNA in the circulation as a predictor of postsurgical recurrence of hepatocellular carcinoma: a prospective study. Hepatology 35 (2002), 853–860.
20. [20] Jeng, K.S., Sheen, I.S., Tsai, Y.C., Circulating messenger RNA of alpha-fetoprotein: a possible risk factor of recurrence after resection of hepatocellular carcinoma. Arch. Surg 139 (2004), 1055–1060.
21. [21] Liu, Y., Wu, M.C., Qian, G.X., Zhang, B.H., Detection of circulating hepatocellular carcinoma cells in peripheral venous blood by reverse transcription-polymerase chain reaction. Hepatobiliary Pancreat. Dis. Int 1 (2002), 72–76.
22. [22] Schmilovitz-Weiss, H., Stemmer, S.M., Liberzon, E., Avigad, S., Sulkes, J., Belinki, A., et al. Quantitation of alpha-fetoprotein messenger RNA for early detection of recurrent hepatocellular carcinoma: a prospective pilot study. Cancer Detect. Prev 30 (2006), 204–209.
23. [23] Tang, S., Yuan, Y., He, Y., Pan, D., Zhang, Y., Liu, Y., et al. Genetic polymorphism of interleukin-6 influences susceptibility to HBV-related hepatocellular carcinoma in a male Chinese Han population. Hum. Immunol 75 (2014), 297–301.
24. [24] Yang, Y., Jin, L., He, Y.L., Wang, K., Ma, X.H., Wang, J., et al. Hepatitis B virus infection in clustering of infection in families with unfavorable prognoses in northwest China. J. Med. Virol 85 (2013), 1893–1899.
25. [25] Robinson, P.J., Imaging liver metastases: current limitations and future prospects. Br. J. Radiol 73 (2000), 234–241.
26. [26] Bialecki, E.S., Di Bisceglie, A.M., Diagnosis of hepatocellular carcinoma. HPB (Oxford) 7 (2005), 26–34.
27. [27] Johnson, P.J., The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin. Liver Dis 5 (2001), 145–159.